Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · IEX Real-Time Price · USD
3.490
+0.400 (12.94%)
At close: May 1, 2024, 4:00 PM
3.220
-0.270 (-7.74%)
After-hours: May 1, 2024, 7:24 PM EDT
Lexaria Bioscience Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Lexaria Bioscience stock has a target of 12, which predicts an increase of 243.84% from the current stock price of 3.49.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 5, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for LEXX is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Mar '24 | Apr '24 |
---|---|---|
Strong Buy | 1 | 1 |
Buy | 0 | 0 |
Hold | 0 | 0 |
Sell | 0 | 0 |
Strong Sell | 0 | 0 |
Total | 1 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Maxim Group | Maxim Group | Strong Buy Maintains $3 → $12 | Strong Buy | Maintains | $3 → $12 | +243.84% | Mar 5, 2024 |
Maxim Group | Maxim Group | Strong Buy Initiates $2 | Strong Buy | Initiates | $2 | -42.69% | Jul 21, 2023 |
Financial Forecast
Revenue This Year
491.13K
from 226.21K
Increased by 117.11%
Revenue Next Year
994.50K
from 491.13K
Increased by 102.49%
EPS This Year
-0.55
from -1.01
EPS Next Year
-0.50
from -0.55
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 852,600 | 1.0M | n/a | 3.7M | 16.8M |
Avg | 491,130 | 994,500 | n/a | 3.6M | 16.3M |
Low | 147,980 | 955,500 | n/a | 3.4M | 15.6M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 276.9% | 108.5% | - | - | 367.0% |
Avg | 117.1% | 102.5% | - | - | 353.7% |
Low | -34.6% | 94.6% | - | - | 335.9% |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | -0.49 | -0.50 | -0.63 |
Avg | -0.55 | -0.50 | -0.61 |
Low | -0.59 | -0.50 | -0.59 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.